USFDA concludes GMP inspection of Biocon’s API facility in Visakhapatnam

24 Jun 2024 Evaluate

The U.S. Food and Drug Administration (USFDA) has concluded a GMP inspection of Biocon’s API facility (Site 5), located at Visakhapatnam, Andhra Pradesh, on June 21, 2024. Four observations were cited at the end of the Inspection, which the company will be addressing within the stipulated time.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.


Biocon Share Price

364.55 -2.00 (-0.55%)
21-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.55
Dr. Reddys Lab 1155.50
Cipla 1369.55
Zydus Lifesciences 876.10
Lupin 2139.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×